Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
YD

NASDAQ · YDESW

YD Bio Limited Warrants

Healthcare · Biotechnology

$0.60

Up+$0.10 (+19.98%)

Updated Oct 10, 2026, 7:25 AM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
3.98M
P/E ratio
-14.54
Dividend yield
0.00%
52-week range
$0.19 – $0.84
Volume
5.42K
Avg. volume
80.12K

Price performance · YDESW

YDESW price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

YDESW closed at $0.60 after 20 trading sessions, up 50.01% for the selected period.

Last close
$0.60
Period change
+50.01%
Period low
$0.36
Period high
$0.80
Daily close
View OHLC price history
YDESW OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$0.5926$0.60$0.563$0.59995.42K
Oct 8, 2026$0.5083$0.54$0.4876$0.504.27K
Oct 7, 2026$0.7899$0.7899$0.60$0.651.43K
Oct 6, 2026$0.4582$0.53$0.4582$0.533.39K
Oct 5, 2026$0.76$0.79$0.39$0.620318.12K
Oct 2, 2026$0.70$0.73$0.5578$0.6744.09K
Oct 1, 2026$0.7845$0.835$0.67$0.728741.61K
Sep 30, 2026$0.725$0.819$0.725$0.799912.71K
Sep 29, 2026$0.7099$0.76$0.7025$0.75194.48K
Sep 28, 2026$0.575$0.7499$0.5733$0.7099168.61K
Sep 25, 2026$0.50$0.5733$0.475$0.573319.2K
Sep 24, 2026$0.3498$0.525$0.325$0.5249113.35K
Sep 23, 2026$0.36$0.36$0.36$0.361.01K
Sep 22, 2026$0.33$0.425$0.33$0.363.31K
Sep 18, 2026$0.3701$0.3701$0.36$0.3611.76K
Sep 17, 2026$0.3261$0.495$0.3101$0.36268.94K
Sep 16, 2026$0.352$0.3772$0.3385$0.35764.52K
Sep 15, 2026$0.39$0.39$0.3252$0.38994.34K
Sep 14, 2026$0.41$0.45$0.39$0.399.68K
Sep 11, 2026$0.3999$0.3999$0.3999$0.3999207

Latest YDESW news

The latest Smart Investors Daily articles mentioning YDESW.

Stock researchCompany · Overview

YDESW research

Overview

Company profile and research snapshot.

Company profile

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced its financial results for the six months ended June 30, 2026. Management Commentary“The first half of 2026 marks a historic turning point for YD Bio, highlighted by our transition to bottom-line profitability and a remarkable 315% surge in top-line revenue,”

Yahoo · Aug 25, 2026

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced the publication of a peer-reviewed review article in Nutrients, an international open-access journal published by MDPI (Multidisciplinary Digital Publishing Institute). The article, titled “Beyond Bone Health: Exploring the ‘Heart–Brain–Bone’ Axis Modulated b

Yahoo · Aug 11, 2026

YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

Two chrono-nutrition formulations — a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula — were developed in collaboration with the Taiwan CDHA and FHI. The Company intends to expand this approach by exploring additional opportunities for collaboration with other physicians and healthcare organizations. TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylati

Yahoo · Aug 4, 2026

YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research

Published in Bioengineering, a collaborative study with Taipei Medical University researchers identifies key molecular candidates to help guide the development of regenerative therapies for corneal disease. TAIPEI, Taiwan, Aug. 04, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today highlighted the publication of a new peer-reviewed study in th

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By